International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

Focus on Psoriasis: A Report from the 2022 Society for Investigative Dermatology (SID) Annual Meeting

022 SID Congress Report Blog Graphic

The Society of Investigative Dermatology (SID) Annual Meeting returned to an in-person format in 2022 for the first time in two years. The meeting was held as a hybrid, in-person meeting in Portland, Oregon, with virtual access to pre-recorded lectures and posters available afterward. The following congress report includes a summary of the Eugene Farber lecture, three IPC lectures, and seven IPC poster presentations, all with a focus on psoriasis. You can download the full report or read on for a brief look at some of the highlights.


Each year, the prestigious Eugene Farber lecture is awarded to an eminent psoriasis investigator. This year, the lecture was awarded to the IPC Board Member Dr. Johann Gudjonsson, MD, PhD. The lecture was titled Has the Riddle of Psoriasis Been Finally Solved – Is it Time to Move On?” Dr. Gudjonsson discussed the impressive advances in psoriasis research in the past two decades. Yet, Dr. Gudjonsson explains the obstacles that must be extensively addressed in future psoriasis research, and no, “it is not yet time to move on.”


  • April Armstrong, MD, MPH, IPC Councilor, presented “Real-World Data Using Medical and Administrative Records.” She focused on the advantages and disadvantages of administrative claims data retrieved from insurance companies versus electronic health/medical records data. She discussed their application in research work and considerations by regulatory authorities.
  • Dr. Nick Reynolds, BSc, MBBS, MD, FRCP, IPC Councilor, presented “Real-World Data and Psoriasis: A European Perspective.” He explained the strengths and weaknesses of real-world data and registries and presented interesting results from psoriasis registries.
  • Alexis Ogdie, MD, MSCE, presented “Innovations in Real-World Data.” She discussed the knowledge gaps that real-world data can answer, explained pragmatic trials, and highlighted future opportunities for innovation of real-world data.


  • Manan Mehta, BS, presented “Your Pores and the Outdoors: Investigating the Association between Pollution and Inflammatory Dermatological Diseases,”– a study highlighting a significant relationship between air pollution (Particulate Matter 2.5) and three inflammatory skin conditions; psoriasis, atopic dermatitis, and hidradenitis suppurativa.
  • George Gondo, MA, the National Psoriasis Foundation (NPF), presented “Understanding Health Disparities among Patients with Psoriasis: Results from National Psoriasis Foundation Annual Surveys 2019 – 2021”. The survey showed the presence of considerable health disparities and differences in psoriasis severity among psoriasis patients of different ethnic groups.
  • Dr. Andrew Blauvelt, MD, MBA, IPC Board Member, presented “Psoriasis Resolution in Challenging Body Areas with Ixekizumab: Response Trajectories by Patient Profile Clusters Over Time.” The study applied machine learning to define Ixekizumab-response clusters. It concluded a rapid and stable complete clearance, including resolution of nail, scalp, and palmoplantar psoriasis with Ixekizumab for most patients.
  • Dr. Megan H Noe, MD, MPH, MSCE, presented “The Patient Perspective on Vaccine Uptake in Adults with Psoriasis and Eczema.” The study showed that psoriasis and eczema patients identified access to appointments and side effects concerns as the most common barriers to receiving recommended adult vaccinations.
  • Dr. Qinmengge Li, BS, MS, presented “Kullback-Leibler Divergence Model to Integrate Genetic and Genomic Information to Assess Drug Response for Psoriatic Patients.” This study revealed the feasibility of using statistical techniques to integrate and analyze information from two independent sets of genetic and genomic data to assess drug response and improve the prognostic prediction accuracy.
  • Dr. Álvaro Gonzales-Cantero, MD, PhD, 2021 IPC Fellow, presented “HDL Composition, Particle Number and Size is Associated with Non-Calcified Coronary Plaque in Psoriasis.” The study concluded that measuring HDL particle number and size using magnetic resonance spectroscopy can be a biomarker for the early detection of subclinical atherosclerosis in psoriasis.
  • Michael D Howell, PhD, presented “A Novel Expression Based, Non-Invasive Method to Differentiate Atopic Dermatitis and Psoriasis.” This study demonstrates the use of non-invasive epidermal skin samples to differentiate psoriasis from atopic dermatitis patients based on a molecular RNA signature of IL-13, CCL17, IL-17A, and NOS2.
Finally, the growing role of artificial intelligence and machine learning in psoriasis research was well-recognized in the scientific sessions of the meeting. For a more in-depth read, please download the full report.

See Upcoming Events

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.


Recent Posts

Remembering Dr. Hoseah Waweru: A Beacon of Hope and Inspiration in the Fight Against Psoriasis

Psoriasis in Older Patients: Key Considerations and Best Practices for Effective Management

Getting to Know IPC’s Board Member Lone Skov: What Inspired Me to Specialize in Psoriasis

Also Read

Generalized Pustular Psoriasis

New IPC Guidelines on Generalized Pustular Psoriasis

Learn about the new global diagnostic criteria for Generalized Pustular Psoriasis as set by the International Psoriasis Council. Discover the essential features, the importance of accurate diagnosis, and the expected global impact on patient care.

Read More
Psoriasis bioengineering advances

Commentary: An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis

This commentary provides expert analysis on recent research findings, clinical trial results, and the promising future of therapies for individuals with moderate to severe plaque psoriasis. Uncover the latest advancements in psoriasis treatments, focusing on the significant impact of new biological agents and oral IL-23 receptor antagonists.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.